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Abstract
The high prevalence of smoking in schizophrenia of European background may be related to smoking’s reducing clinical
symptoms and medication side effects. Because smoking prevalence and its associations with clinical phenotypes are less
well characterized in Chinese than European patients with schizophrenia, we assessed these smoking behaviors using
clinician-administered questionnaires and the Fagerstrom Test for Nicotine Dependence (FTND) in 776 Chinese male
schizophrenia and 560 control subjects. Patients also were rated on the Positive and Negative Symptom Scale (PANSS), the
Simpson and Angus Extrapyramidal Symptom Rating Scale (SAES), and the Abnormal Involuntary Movement Scale (AIMS).
We found that the schizophrenia patients had a higher lifetime incidence of smoking (79% vs 63%), were more likely to be
heavy smokers (61% vs 31%), and had lower smoking cessation rates (4% vs 9%) (all p,0.0001) than controls. Among the
schizophrenia patients smoking prevalence increased with age, with the largest difference from controls in the age cohort
of 55–75 years: 75% vs 46% (p,0.0001). Among the schizophrenia smokers 73% started to smoke before the onset of their
illness by an average of 7.6 years. The patients with schizophrenia who were current smokers scored significantly lower on
the PANSS negative symptom subscore (p,0.005), and on the SAES symptom scale (p,0.04; Bonferroni corrected p.0.05)
than the non-smoking patients. These results suggest that Chinese males with schizophrenia smoke more frequently than
the general population. Further, smokers with schizophrenia may display fewer negative symptoms and possibly less
parkinsonism than non-smokers with schizophrenia.
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Introduction
Schizophrenia patients of European ancestry have three to four
times higher smoking rates than the general population and other
severely mentally ill patients [1–4]. Studies show that after
correcting for possible confounds, such as marital and socio-
economic status, alcohol use, antipsychotic use or institutionaliza-
tion, higher rates of smoking persist in schizophrenia across
cultures and countries [1,2,5]. Furthermore, smokers with
schizophrenia consume more cigarettes, extract more nicotine
per cigarette, prefer brands higher in nicotine, have higher blood
nicotine levels, and have lower success rates in attempts to stop
smoking than smokers with no mental illness [3,6–8]. High rates of
smoking among those with psychotic disorders may contribute to
the 20% reduction in life expectancy reported in this population
[9]. It is unknown why there is such widespread smoking in
patients with schizophrenia. Some evidence seems to support that
nicotine may help alleviate negative symptomology, reduce side
effects of antipsychotic medications, and possibly ameliorate
cognitive deficits [1,10].
However, evidence is inconsistent regarding the association
between smoking and symptoms of schizophrenia [11]. Indeed, in
spite of support from animal studies [12], very limited clinical data
corroborate an association between smoking and a reduction in
negative symptoms [11]. For example, higher levels of both
negative and positive symptoms have been found in smoker than
in non-smoker schizophrenia, and acute cigarette smoking
following 6–12 hours of abstinence reduces schizophrenia’ nega-
tive symptoms, but several studies find no differences in negative
symptoms between smokers and non-smokers [13–19]. Others
have divided schizophrenia smokers into subgroups based on
smoking severity and shown lower levels of negative symptoms and
higher levels of positive symptoms in heavy smokers than light
smokers [6,15]. Recently, we found fewer positive symptoms in
Chinese schizophrenia smokers than non-smokers, and smoking
more cigarettes correlated with fewer negative symptoms [20].
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smoking and symptoms of schizophrenia.
Significantly less Parkinsonism is reported in neuroleptic treated
patients with schizophrenia who smoke [16]. This may represent a
protective effect of cigarette smoking, since smoking behaviors
start decades before the onset of parkinsonism [1,16]. The
association between tardive dyskinesia (TD) and smoking is less
clear. Studies show lower rates [21], higher rates [22,23] and no
relationship between smoking and TD [16,18].
Thus, smoking in schizophrenia may be associated with reduced
clinical symptoms and medication-induced extrapyramidal side
effects. However, the prevalence of smoking and its associations
with demographics and clinical phenotypes have been relatively
under-examined among Chinese schizophrenia patients in spite of
the large proportion of Chinese who smoke [24,25,26]. Gender is
a critical demographic determinant of smoking behaviors in all
countries, particularly in China, where smoking is extraordinarily
rare among females in the general population (male/female:
67.1% vs. 7.1%) and in patients with schizophrenia (male/female:
52.0% vs. 4.5%) [1,3,19,26,27]. Because the smoking rate for our
schizophrenia female inpatients is also low (5.0%) [20], we focused
on male subjects in this study. The purpose of this study therefore
was to investigate the smoking prevalence and its associations with
clinical symptoms and medication-induced extrapyramidal symp-
tom severity in a large sample of Chinese male patients with
schizophrenia.
Materials and Methods
Subjects
We approached all inpatients in the Beijing Hui-Long-Guan
Hospital, a Beijing City owned psychiatric hospital, and HeBei
Province Veteran Psychiatric Hospital in BaoDing city, which is
about 50 miles away from Beijing using a cross-sectional
naturalistic design. The recruitment criteria included: 1) age 25–
75 years, Han Chinese; 2) confirmed DSM-IV diagnosis of
schizophrenia; 3) with at least 5 years of illness; 4) had been
receiving stable doses of oral antipsychotic drugs for at least 12
months before entry into the study. The mean age of the patients
was 47.369.8 years. All patients were of the chronic type, with a
mean illness course of 22.367.2 years. Patients were hospitalized
for an average of 8.966.9 years. Since these patients were
hospitalized, there were restrictions on their smoking, with a fixed
schedule for smoking: three or four times each day, and
30 minutes each time. During the smoking period, a patient could
smoke as many cigarettes as he/she liked. The patients or their
family members had to purchase the cigarettes, with occasional
supplemented supplies from their friends or employers, but at very
low prices for most cigarette brands. Thus, smoking was not
economically limited, and for the assessment peroid of these
baseline smoking behaviors no patients were engaged in any
behavior reinforcement schedules using cigarettes. The patients in
the present study could be considered a representative sample of
institutionalized chronic patients with schizophrenia in China.
The resident registration files provided a random sample of
control subjects (age 25–75 years) who lived in the Haidian District
of Beijing, and we sent each subject a letter explaining the purpose
of the study. Of the 812 eligible subjects, 560 completed the
baseline interview (participation rate: 69%). Local officials and
health centers arranged for the interviews and measurements to
take place at the center office at times convenient to the
participants. All participants were interviewed by trained investi-
gators supervised by a research psychiatrist. A clinical interview
was used to exclude potential controls with Axis I disorders by a
research psychiatrist.
We obtained a complete medical history, physical examination
and laboratory tests from patients and control subjects. All were in
good physical health. Participants were not dependent on alcohol
or other substances other than tobacco, based on their self-report.
Cannabis use in patients with schizophrenia is extremely rare in
China, and our inpatient sample was in a confined setting with
monitoring for alcohol and other substances (and any smoked
cannabis use would have been particularly easy to detect). All
subjects gave signed, informed consent to participate in the study,
approved by the Institutional Review Board (IRB), Beijing
HuiLongGuan hospital. If a participant had reduced capacity/
ability to consent, his/her parents or guardians consented on his or
her behalf.
Measures
Each subject filled out a detailed questionnaire that recorded
general information, sociodemographic characteristics, smoking
behavior, and medical and psychological conditions. In addition,
we administered a cigarette smoking questionnaire to record
smoking history and family history of smoking from each subject,
including the pack years. The Chinese translation of the
standardized Fagerstrom Test for Nicotine Dependence (FTND)
was employed to measure the degree of nicotine dependence [28].
Additional information was collected from available medical
records and collateral data (from family and/or treating clinician).
Additional visits were requested for subjects with missing or
ambiguous data.
We divided the subjects into groups based on their smoking
history and FTND scores. Never smokers were defined as individuals
who had smoked less than 100 cigarettes during their lifetime.
Former smokers were defined as persons who had previously smoked
more than one cigarette each day but had quit smoking for more
than 1 year. Current smokers were defined as persons who smoked
more than one cigarette each day and have smoked for more than
1 year. Ever smokers included current and former smokers. Smoking
cessation rates were measured as the ratio of former smokers to the
total subjects. Heavy smokers were defined as persons who had
smoked 15 or more cigarettes per day, or rated with a score of $6
in the FTND [29].
Clinical Measures
Four psychiatrists who had previously completed training in
scoring the Positive and Negative Syndrome Scale (PANSS)
assessed patient psychopathology using it. After training, repeated
assessment showed that they maintained an inter observer
correlation coefficient greater than 0.8 for the PANSS total score.
The same clinical psychiatrists assessed medication side effects,
Parkinsonism and akathisia using the Simpson and Angus Rating
Scale (SAES) and tardive dyskinesia using the Abnormal
Involuntary Movement Scale (AIMS).
Statistical Analysis
Demographic and clinical variables of the smoker and non-
smoker groups were compared using t-tests and analysis of
variance (ANOVA) for continuous variables and chi-squared for
categorical variables. Cross-comparisons were performed to
calculate smoking prevalence by diagnostic and age group. Odds
ratios (OR) derived from logistic regression analyses compared
smokers and non-smokers among the patients with schizophrenia
and controls after correcting for the related variables. Relation-
ships between clinical variables were examined by calculating
Pearson correlation coefficients. Bonferroni corrections were
Smoking in Schizophrenia
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2 tailed with significance level set at 0.05.
Results
Seven hundred and eighty-nine patients were asked to
participate, and 776 consented. However, some subjects did not
complete the questionnaire or clinical measures fully; therefore,
numbers vary slightly in different categories. The demographic
comparisons of the subjects are shown in Table 1.
Comparison of smoking between schizophrenia patients
and controls
We compared current smokers with non-smokers (former
smokers and those who had never smoked) on demographic and
clinical variables for the 776 patients with schizophrenia and the
560 healthy controls in Table 1. As shown, the frequency of ever
smoking was 79.6% (618/776) for the patients with schizophrenia
and 63.0% (353/560) for the control group, with an OR of 2.29
(95% CI: 2.22–2.36; X
2=45.2, df=1, p,0.0001). This difference
remained significant after using logistic regression to control for
the socio-demographic confounds, such as age, education, marital
and socio-economic status, and alcohol use (X
2=40.6, p,0.0001,
adjusted odds ratio=2.17; 95% confidence interval, 1.42–2.98).
The frequency of current smoking was 76% for the schizo-
phrenia patients and 54% for the control group, with an OR of
2.67 (95% CI: 2.59–2.74; X
2=69.8, df=1, p,0.0001). In
addition, the frequency of heavy smoking was 61% (476/776)
for the patients with schizophrenia and 31% (176/560) for the
control group (OR=3.46; 95% CI: 3.35–3.55; X
2=116.5, df=1,
p,0.0001). The prevalence of smoking cessation was significantly
lower in patients with schizophrenia than normal controls [30 of
776 (4%) vs. 51 of 560 (9%); OR=2.50, 95% CI: 2.24–2.80;
X
2=13.8, df=1, p,0.0001].
Smoking among the patients with schizophrenia
Of the 618 patients with schizophrenia who had ever smoked,
73% started to smoke before the onset of their schizophrenia, 5%
at the onset of illness, and 22% after the onset. The mean age at
starting smoking preceded the mean age at onset of illness by
7.6610.2 years. In addition, there was a positive correlation
between age at starting smoking and the age at onset of illness in
all patients (r=0.12, p=0.005).
Smokers and non-smokers among the patients with
schizophrenia
Smokers were older (mean age=47.8, SD=9.2) than non-
smokers(mean age=45.9,SD=11.4)(t=2.22,df=774,p=0.024),
as shown in Table 2. Current smokers also had significantly lower
levels of negative symptoms (t=22.85, df=762, p,0.005)
(Bonferroni correction: p,0.01) and were significantly more likely
to be receiving clozapine (X
2=5.29, df=1, p,0.05). After
controlling for the type, the dose (chlorpromazine equivalent) and
duration of treatment with antipsychotic drugs, as well as the other
related variables such as age, and the number of hospitalizations,
the significant difference in negative symptoms between smokers
and non-smokers remained (p,0.01). Furthermore, we did not find
any significant relationships between smoking and the class, the
dose, and duration of treatment with antipsychotic drugs (all
p.0.05). Current smokers exhibited less Parkinsonism (p=0.04),
but no difference in tardive dyskinesia on the AIMS compared to
non-smokers (p.0.05). However, the Parkinsonism result did not
pass the Bonferroni test.
Discussion
We found that among Chinese patients with schizophrenia: (1)
current smoking, ever smoking and heavy smoking prevalence was
significantly higher than in the general population; (2) smoking
cessation rates were significantly lower than in the general
population; (3) smokers with schizophrenia had significantly lower
PANSS negative symptom scores and tended to have less
parkinsonism than non-smokers.
An association between schizophrenia and smoking
behaviors
Our results are consistent with other studies that report high rates of
current cigarette smoking and lower smoking cessation rates in patients
with schizophrenia than in controls [1,2]. These associations have been
reliably shown in schizophrenia patient cohorts from different
demographical areas supporting a possible biological explanation [1].
We also found that 73% of schizophrenia patients started to smoke
before the onset of their schizophrenia illness with an average of 7.6
years before illness onset. Thus, pharmacotherapy during schizophre-
nia or its prodromal period is unlikely to explain the association of this
disorder with smoking. The higher frequency of current smoking in
patients with schizophrenia appears to result from both a lower quitting
rate occurring and a higher and possibly younger initiation rate in this
population [1,30]. As a neurobiological mechanism for this association
Freedman et al. [31] have described a genetic neurophysiological
abnormality in patients with schizophrenia and their relatives, which
nicotine administration temporarily corrects. This abnormality is
associated with dysfunctional hippocampal alpha 7 nicotine receptors.
Two recent epidemiological surveys showed that new psychotic
symptoms were 70% more likely in smokers than nonsmokers in the
British general population [32], and that cigarette smoking was
associated with greater schizotypy in first degree relatives of patients
with schizophrenia [33]. Thus, heritable factors may make subjects
who are vulnerable to schizophrenia more prone to become smokers
and to start smoking at a young age [1]. Further studies are warranted
to investigate this possibility directly.
Cigarette smoking, symptoms and medication side
effects
Two main sub-hypotheses are usually included in the self-
medication hypothesis for high smoking rates in schizophrenia:
smoking reduces side-effects of antipsychotics; and nicotine may
Table 1. Demographics of male patients and male control
subjects.
Schizophrenia
(N=776)
Controls
(N=560)
Age (years) 46.269.2 46.7612.6
Education (years) 9.762.5 9.763.3
Smoking
Current smoker 588(75.8%) 302(53.9%)
Former smoker 30(3.9%) 51(9.1%)
Never smoker 158(20.4%) 207(37.0%)
doi:10.1371/journal.pone.0030937.t001
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cognitive symptoms [15]. Our study supports these hypotheses
prediction that schizophrenia smokers would display significantly
lower negative symptoms. This finding replicates earlier work in
patients with schizophrenia from western regions [13], but is not
consistent with others [14,15,17–19]. Inconsistent findings be-
tween studies may be due to differences in experimental
procedures, acquiring of data, measurement tests, and parameters.
One mechanism of the self-medication hypothesis is that
chronic nicotine can alleviate negative symptoms through
dopaminergic effects. Nicotinic acetylcholine receptors have been
identified on mesolimbic and nigrostriatal dopaminergic neurons
in rats [34], where acute nicotine administration releases
dopamine in the striatum and nucleus accumbens [12] and
chronic nicotine decreases dopamine catabolism in the dorsal
striatum [35]. Since the negative symptoms of schizophrenia are
associated with hypoactivity of dopaminergic systems, smoking
may lessen negative symptoms by increasing dopamine in the
nucleus accumbens [36]. However, positive symptoms are believed
to be associated with subcortical dopamine hyperactivity in
schizophrenia [36], and we did not find any effects of smoking
on positive symptoms. The exact mechanisms for association
between smoking and negative or positive symptoms deserve
further investigation.
Decreased neuroleptic-induced parkinsonism (NIP), as seen in
our schizophrenia smokers replicates some previous studies [16],
but not others [17,23]. A previous study also showed that smoking
was associated with lower levels of antipsychotic induced akathisia
in schizophrenia [18]. Convincing clinical evidence shows an
inverse association between cigarette smoking and lower rates of
idiopathic Parkinson’s disease (IPD) suggesting a protective effect
of smoking [37]. Both IPD and NIP share certain familial,
pharmacological, and biochemical characteristics and some
patients with NIP may have underlying IPD [38]. Thus, cigarette
smoking may prevent, delay the occurrence, or lessen the severity
of NIP through effects on IPD risk factors in a patient. Smoking
might also have two other mechanisms. First, the direct action of
nicotine on enhancing nigrostriatial dopamine release as men-
tioned above. Second, smoking increases neuroleptic metabolism
by inducing hepatic microsomal enzymes [39], which could
contribute to lower antipsychotic blood levels and reduced side
effects of antipsychotic drugs. Since neuroleptic doses were
equivalent for the smokers and non-smokers in our study, cigarette
smoking could have improved symptoms of NIP through both
enhanced dopaminergic functions and decreased antipsychotic
blood levels. Future studies might assess the medication blood
levels to distinguish these mechanisms. However, our finding of
less neuroleptic-induced parkinsonism in patients who smoked was
statistically weak and requires replication.
Limitations of this study
Several factors limit our findings. First, this is a cross-sectional
study design and cannot show direct causality of smoking, whether
beneficial or harmful, in patients with schizophrenia. Second,
although any axis 1 psychopathology was ruled out in the control
group, we did not evaluate any ‘‘axis 2’’ or a ‘‘family history of
schizophrenia/psychotic illness’’ in this population. Since Ester-
berg et al. [33] reported that smoking was more common in
Table 2. Characteristics of Smoking and Nonsmoking Patients with schizophrenia.
Item
Smokers
(n=588) Non-smokers (n=188) t or X
2 df p
Age (yrs) 47.869.2 45.9611.4 2.22 1,774 0.024
Age at onset (yrs) 23.064.7 23.064.8 0.09 1,771 0.93
Education (yrs) 8.864.5 8.662.8 0.44 1,767 0.66
Number of hospitalizations 4.562.8 3.662.5 2.51 1,760 0.006*
Subtypes of Schizophrenia
Paranoid type 165 (28.1%) 59 (31.4%)
Disorganized type 58 (9.9%) 15 (8.0%)
Residual Type 27 (4.6%) 6 (3.2%)
Undifferentiated type 321(54.6%) 102 (54.3%)
Others 17 (2.9%) 6 (3.2%)
Neuroleptic dose 450.06442.4 427.66251.9 0.64 1,767 0.51
(chlorpromazine equivalents, mg/day)
Antipsychotic types
Clozapine 288(79.6%) 74(20.4%)
Non-clozapine 300(72.5%) 114(27.5%)
PANSS total score 58.8615.2 61.1616.9 21.71 1,762 0.08
P subscore 11.464.8 11.264.4 0.46 1,762 0.64
N subscore 22.867.8 24.769.0 22.85 1,762 0.005*
G subscore 24.665.9 25.266.8 21.12 1,762 0.28
Parkinsonism score 1.362.1 2.262.4 22.12 1,764 0.04
AIMS total score 4.664.4 4.564.7 0.31 1,762 0.76
BMI (kg/m2) 24.363.7 24.564.2 20.64 1,548 0.52
*indicated the Bonferroni corrected p value, * p,0.05.
doi:10.1371/journal.pone.0030937.t002
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may have had a small percentage of these persons as controls.
Because the community rate of schizophrenia is about 1% and the
rate of schizotypy is similarly low, the contribution of this potential
confound to overestimating the smoking rate in our controls seems
very small. Also, we did not evaluate ‘‘subsyndromal psychotic
symptoms’’ in the control population, which is potentially
important among younger controls who had not passed through
the age of risk for developing schizophrenia. However, we had a
relatively older sample (mean 46 years) and did not find that the
smoking association was weakened among the older patients and
controls. Third, generalizing our study is limited by our sample of
chronically hospitalized male patients, who had more severe
psychopathology and a longer duration of illness than typical
psychotic outpatients or first episode and drug-naı ¨ve patients with
schizophrenia. Fourth, these patients had a long history of almost
20 years of treatment with antipsychotics. While they had been on
their current antipsychotics for at least 12 months (mean treatment
7.5 years), previous antipsychotic treatment, usually with typical
rather than atypical antipsychotic treatment may have influenced
the effects of smoking to some degree. Hence, examination of a less
chronic patient population might show different associations. Fifth,
we did not take into consideration a ‘‘prodromal phase’’ or the
‘‘duration of untreated psychosis’’ in determining that the mean
age at starting smoking was around 7 years before the onset of
clinical illness. The ‘‘prodromal phase’’ is a complex syndrome
that is very difficult to date in its onset and length, but seven years
appears to be rather long for a ‘‘prodromal phase.’’ However,
smoking may be associated with a prodromal period in some
patients with schizophrenia. Sixth, our sample was limited to
males and can not be applied to females. Seventh, there was no
confirmatory measure of smoking in this study, such as expired
breath CO, and cotinine levels. Eighth, while smoking may reduce
negative symptoms, and possibly NIP in the patients in our present
study, the data for medical comorbidity in this group, which could
be considerable given their association with smoking, had not been
collected. Thus, whether smoking is harmful or beneficial to
patients deserves further investigation.
In conclusion, our results extend previous studies linking heavy
smoking, greater smoking frequency and lower smoking cessation
rates with schizophrenia to a Chinese population. Patients with
schizophrenia who smoked displayed significantly fewer negative
symptoms and, possibly fewer extrapyramidal side effects lending
support for the self-medication hypothesis. However, due to the
cross-sectional study design, we cannot attribute causality to our
smoking association with schizophrenia. Further studies in first-
episode and drug naı ¨ve patients with schizophrenia would help
clarify the interrelationship between clinical symptoms, antipsy-
chotic-induced side effects and smoking.
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